The discovery of selective KRAS G12C inhibitors presents great promise for the treatment of lung cancers that are driven by this mutation, but these inhibitors will not be effective for other cancers with lower prevalence of KRAS G12C mutations, such as colorectal (12%) and pancreatic (4%) cancers [10]. Here, KRAS is linked to lung carcinoma.